Daclatasvir + Rosuvastatin = Precautionary

Effect on Concentration

Daclatasvir
No change
Applies within class?
No
Rosuvastatin
Increase
Applies within class?
No

Pharmacologic Effects

Daclatasvir
Effect
N/A
Applies within class?
No
Rosuvastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 09-Jul-2018

Summary

Caution is warranted during coadministration of rosuvastatin with daclatasvir, and other substrates of OATP1B1 or BCRP transporters, as daclatavir is an inhibitor. Consider dose adjustment of rosuvastatin, and close monitoring for therapeutic effect and adverse reactions.

Sources

Daclatasvir vs Rosuvastatin ^

Study Design

*This interaction has not been formerly studied, but inferences are drawn from knowledge of the metabolic and transport pathways of each of the drugs.

Study Results

The manufacturer states that coadministration of daclatasvir with inhibitors or inducers of either CYP3A or P-gP may alter daclatasvir concentrations.

Study Conclusions

Inhibitors of P-gP or CYP3A may increase daclatasvir concentrations, while inducers of this enzyme and transport protein may decrease daclatasvir concentrations.

References

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Biffano M, Eley T. A review of daclatasvir drug-drug interactions. Advances In Therapy. 2016; 11: 1867-1884.